Prospective genetic screening decreases the incidence of Abacavir hypersensitivity reactions in the Western Australian HIV cohort study
Rauch, A., Nolan, D., Martin, A., McKinnon, E., Almeida, C. and Mallal, S. (2006) Prospective genetic screening decreases the incidence of Abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clinical Infectious Diseases, 43 (1). pp. 99-102.
*Subscription may be required
Abacavir therapy is associated with significant drug hypersensitivity in ∼8% of recipients, with retrospective studies indicating a strong genetic association with the HLA-B*5701 allelle. In this prospective study, involving 260 abacavir-naive individuals (7.7% of whom were positive for HLA-B*5701), we confirm the usefulness of genetic risk stratification, with no cases of abacavir hypersensitivity among 148 HLA-B*5701–negative recipients.
|Publication Type:||Journal Article|
|Murdoch Affiliation:||Institute for Immunology and Infectious Diseases|
|Publisher:||University of Chicago Press|
|Copyright:||© 2006 by the Infectious Diseases Society of America|
|Item Control Page|
Downloads per month over past year